2. 2
Patient narratives are written for deaths, serious adverse events (SAEs), or
adverse events (AEs) of special clinical interest (eg, AEs associated with the
mechanism of action being studied, laboratory results of special interest,
regulatory requirements etc.) and those leading to permanent
discontinuation from a clinical trial. Patient narratives form an important
component of clinical study reports (CSRs) and pharmacovigilance activities
(e.g. post marketing safety reports).
Also referred as patient safety narratives.
A patient safety narrative provides a full and clinically relevant,
chronological account of the progression of an event experienced during or
immediately following a clinical study.
12-26-2016
Katalyst Healthcares & Life Sciences
3. As per International Conference on Harmonisation (ICH) E3 (Section 12.3.2), a patient narrative
should describe :
The nature, intensity and outcome of the event
Clinical course leading to the event
Timing of study drug administration
Relevant laboratory measures
Counter measures
Action taken with the study drug in relation to the event
Post mortem findings (if applicable)
Investigator’s and sponsor’s opinion on causality
Additionally, patient identifier, age, gender, clinical condition, disease being treated, relevant
medical history, concomitant and prior medications should be included.
All this information is extracted from the source files (e.g. Council for International Organisations of
Medical Sciences [CIOMS] form, Case Report Form [CRF], MedWatch form, Data Clarification Form
[DCF], summary tables, and listings). Sometimes, the CIOMS form can be directly attached as an
appendix to the CSR.
3
12-26-2016
Katalyst Healthcares & Life Sciences
4. Some aspects that you should clarify include:
Sentence structures (e.g. some clients prefer to start a
sentence with a date)
Date formats
Which medical history and concomitant medications are
considered relevant
Inclusion or exclusion of normal ranges for laboratory
results
Trade or generic names for drugs
4
12-26-2016
Katalyst Healthcares & Life Sciences
5. The information provided in the narrative should be consistent
with the data appropriately reflected in all the other relevant ICH-
E2B(R2) data elements of the ICSR.
During the interim arrangements, the case narratives included in
the ICSRs submitted to the competent authorities in Member
States by marketing authorisation holders, should not be
modified or deleted when the ICSRs are forwarded to the
EudraVigilance database by the competent authorities.
New information should be clearly identifiable in the case
narrative (data element ICH-E2B(R2) B.5.1) and provided in a
structured format in the applicable ICH-E2B(R2) data elements.
5
12-26-2016
Katalyst Healthcares & Life Sciences
6. CT narrative Template:
Protocol/Study ID: XXXX
Study Title/Study description: Post-Marketing Surveillance of DRUG mg (ingredient) to Evaluate Its Safety and Efficacy.
Screening number/Randomization No: XXX-XX-XXX
Patient ID/Subject ID: XXXX-XXXX
This case was reported by an investigator on DD-MMM-YYYY.
This case refers to a XX-year-old female/male patient who had liver function test (LFT) elevation during Drug therapy.
The patient's relevant medical history included:
The patient's concomitant medications included
The patient's laboratory data on (Pre therapy)
The patient was administered with
About AE/SAE
The patient's laboratory data on (Post therapy)
Action taken with respect to Drug was no change and the patient was recovered from the event LFT elevation on DD-MMM-
YYYY.
The reporter assessed the causality between the medication and the event LFT elevation as possibly related.
6
12-26-2016
Katalyst Healthcares & Life Sciences
7. Spontaneous Narrative Template:
This initial spontaneous case was reported by a physician via sales representative via Partner, on XX-
XXX-XXXX.
This case refers to a XX-year-old male/female patient who experienced increased alkaline
phosphatase levels following therapy with Drug (ingredient).
The patient's medical history was not reported. Current condition included Crohn's disease.
The patient's concomitant medications were not reported.
The patient commenced therapy with Drug (unspecified dose), weekly via intravenous route
indicated for Crohn's disease on since an unspecified date in XXX-XXXX.
On an unspecified date, since the start of Drug therapy, the patient suffered from increased alkaline
phosphatase levels.
It was reported that the other liver values were in normal ranges.
At the time of this report, action taken with Drug was ongoing and the outcome of the event was
unknown.
The reporter assessed the case to be non-serious and the causality between the medication and the
event was not reported.
7
8. This initial [serious/non-serious] [spontaneous/literature] report, which originated from [country] was received by [Marketing Partner’s
Name] on [date DD MMM YYYY].
Information has been received from a [reporter] concerning a [age] year old [male/female] with a medical history of [history, including
the duration of concurrent illness, age at diagnosis, date of diagnosis or onset date not reported]. The patient commenced treatment
with [SUSPECT PRODUCT], dose, frequency, on date for indication. Concomitant therapy included [generic name of relevant
concomitant drugs with/without indication if appropriate. Or provide a general statement such as subject was also receiving multiple
concomitant medications, with or without indications (for example, he/she was taking multiple medications for pain, hypertension and
depression). Note that concomitant medications include those medications taken within a reasonable time frame (30 days) prior to
the onset of an adverse event and medications taken by the subject at the time of the reported adverse event.]
On [date MM DDD YYYY], the subject presented with event [detailed event description including signs, symptoms and details about
hospitalisation including prolongation of existing hospitalisation]. which required hospitalisation.
The subject’s laboratory results on [DD MMM YYYY] were as follows: [list relevant physical findings, exams and laboratory results].
Corrective treatment for the event included [describe medications, procedures, tests, investigations etc.]. [State outcome of event
following treatment (recovered, unresolved, recovered with sequelae (describe sequelae), or death). Note if event resolved
spontaneously].
[Fatal patient outcome details: include date and cause of death, the timing of death in relation to the event onset and suspect drug
therapy duration].
The reporter assessed the events as being serious/non serious [if serious, state reported seriousness criteria] physicians assessment of
intensity of event (e.g. mild, moderate, severe) and relatedness of event to products include reported rationale for causality
assessment.] The final outcome of the event was [state reported outcome] at the time of this report. No further information was
provided.
[Company’s medical assessment and comment: Include the facts that the company believe are relevant to the case].
8
9. Follow-up information received on [DD-MMM-YYYY]
from [source] (or Source Data Verification received
on…., or Data Correction Made on…., etc):
[Briefly describe additions, corrections and/or
9
12-26-2016
Katalyst Healthcares & Life Sciences
10. Literature Narrative Template: This is a report from literature which described Anti-TNF, Infliximab And
Adalimumab, Can Be Effective In Eosinophilic Bowel Disease: A Report Of Eight Pediatric Cases.
Literature source Turner D, Wolters VM, Russell RK, Shakhnovich V, Muise AM, Ledder O, Ngan B, Friesen C.
Anti-TNF, Infliximab And Adalimumab, Can Be Effective In Eosinophilic Bowel Disease: A Report Of Eight
Pediatric Cases. J Pediatr Gastroenterol Nutr. 2012 Dec 5;6(6):659-65..
Abstract: Eosinophilic enterocolitis (EEC) is an emerging distinct inflammatory bowel disease of unknown
etiology. There are no published data on the effect of infliximab or adalimumab for the treatment of refractory
cases. METHODS: A report of all pediatric EEC cases treated with anti-TNF, identified after an open international
call. RESULTS: We describe here the first eight children with refractory EEC who were treated with infliximab
(75% males; mean age at diagnosis 8.6±4.03 (range 1.6-14 years), mean age at infliximab treatment 11.7±4.4
(range 4.2-16 years)). Allergic and infectious causes of EEC were excluded in all cases. Rapid and complete
clinical remission was documented in 6 (75%) children following the induction infusions; 3 (38%) with
endoscopic remission, 2 (25%) with endoscopic improvement and one unknown. Four of the six responders had
secondary loss of response and were switched to adalimumab, three of whom with sustained remission using
high doses. Overall, the six responders were followed for a median of 7 years (range 4-12; IQR 6.4-8.8 years)
without evidence of developing Crohn's disease or ulcerative colitis. The only case with macroscopic findings on
endoscopy was a primary non-responder.
This file represents a patient no. 1 of 8. Description regarding patient no: 1
The reporting physician considered the event serious (Medically significant).
Conclusion: Infliximab and adalimumab may be effective in cases of refractory idiopathic EEC.
10
11. Important Points to Remember:
Narrative should be precise and concise.
Double check spell mistakes, spaces, format, flow of narrative in agreed chronology
Do not repeat the information.
Abbreviations should be expanded once.
Globally accepted abbreviations ex: ECG need not be expanded.
Avoid using short forms in narrative.
Always write narrative in third party saying and in past sentences.
Do not change the meaning of narrative by adding own supportive words/conclusion.
The verbatim should be written as it is presented in source document. Use quotation marks to
present strange verbatim terms.
Try to avoid exceeding characters to make successful E2B submission (the narrative field has a
20,000 character limit and the case comment has 2,000 character limit).
Use paragraphs to present narrative in style and logical format.
11
12-26-2016
Katalyst Healthcares & Life Sciences
